FDA grants supplemental application approval for Dupixent (BLA761055)
The FDA has approved the supplemental application for Dupixent (BLA761055) submitted by Regeneron Pharmaceuticals.
Therapeutic Area
Therapeutic area intelligence for IL-13 with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.